Pancreatic Lipid Content Is Not Associated with Beta Cell Dysfunction in Youth-Onset Type 2 Diabetes

Canadian Journal of Diabetes

Volumn 39, Issue 5, 2015, Pages 398-404

  Wicklow, Brandy A ^a,b   Griffith, Angella T ^a   Dumontet, Jacqueline N ^a   Venugopal, Niranjan ^c   Ryner, Lawrence N ^c   McGavock, Jonathan M ^a,b  

^a Manitoba Institute of Child Health   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Adolescent; Lipotoxicity; Nuclear magnetic resonance (NMR) spectroscopy; Pancreas; Steatosis; Type 2 diabetes

Indexed keywords

GLYCINE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; INSULIN; LIPID; SERINE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CAUCASIAN; CELL DAMAGE; CELL FUNCTION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FAT TO WATER RATIO; FEMALE; GENE MUTATION; HETEROZYGOTE; HNF 1ALPHA GENE; HUMAN; INDIGENOUS PEOPLE; INSULIN RESPONSE; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID COMPOSITION; MALE; MEDICAL PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PANCREAS ISLET BETA CELL; PEER GROUP; PROTON NUCLEAR MAGNETIC RESONANCE; GENETICS; LIPID METABOLISM; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADOLESCENT; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; INSULIN-SECRETING CELLS; LIPID METABOLISM; MAGNETIC RESONANCE IMAGING; MALE; PANCREAS; TRIGLYCERIDES;

EID: 84943363219     PISSN: 14992671     EISSN: 23523840     Source Type: Journal    
DOI: 10.1016/j.jcjd.2015.04.001     Document Type: Article

References (48)

1. Stumvoll M., Goldstein B.J., van Haeften T.W. Type 2 diabetes: Pathogenesis and treatment. Lancet 2008, 371:2153-2156.
2. Prentki M., Nolan C.J. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006, 116:1802-1812.
3. Robertson R.P., Harmon J., Tran P.O., et al. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004, 53(Suppl 1):S119-S124.
4. Bacha F., Lee S., Gungor N., et al. From pre-diabetes to type 2 diabetes in obese youth: Pathophysiological characteristics along the spectrum of glucose dysregulation. Diabetes Care 2010, 33:2225-2231.
5. Lee Y., Hirose H., Ohneda M., et al. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: Impairment in adipocyte-beta-cell relationships. Proc Nat Acad Sci U S A 1994, 91:10878-10882.
6. Goh T.T., Mason T.M., Gupta N., et al. Lipid-induced beta-cell dysfunction in vivo in models of progressive beta-cell failure. Am J Physiol Endo Metab 2007, 292:E549-E560.
7. Lee Y., Lingvay I., Szczepaniak L.S., et al. Pancreatic steatosis: Harbinger of type 2 diabetes in obese rodents. Int J Obes 2010, 34:396-400.
8. Perman W.H., Balci N.C., Akduman I. Review of magnetic resonance spectroscopy in the liver and the pancreas. Top Magn Reson Imaging 2009, 20:89-97.
9. Misra D., Gupta V., Sonkar A.A., et al. Proton HR-MAS NMR spectroscopic characterization of metabolites in various human organ tissues: Pancreas, brain and liver from trauma cases. Physiol Chem Physics Med NMR 2008, 40:67-88.
10. Esclassan J., Chemin-Thomas C., Creach Y., et al. High-resolution 1H NMR study of membrane phospholipids in rat pancreas stimulated by caerulein. Pancreas 1994, 9:263-269.
11. Haaga J.R. Magnetic resonance imaging of the pancreas. Radiol Clin North Am 1984, 22:869-877.
12. Smith F.W., Reid A., Hutchison J.M., Mallard J.R. Nuclear magnetic resonance imaging of the pancreas. Radiology 1982, 142:677-680.
13. Vesterhus M., Raeder H., Johansson S., et al. Pancreatic exocrine dysfunction in maturity-onset diabetes of the young type 3. Diabetes Care 2008, 31:306-310.
14. Tushuizen M.E., Bunck M.C., Pouwels P.J., et al. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. Diabetes Care 2007, 30:2916-2921.
15. Szczepaniak L.S., Victor R.G., Mathur R., et al. Pancreatic steatosis and its relationship to beta-cell dysfunction in humans: Racial and ethnic variations. Diabetes Care 2012, 35:2377-2383.
16. van der Zijl N.J., Goossens G.H., Moors C.C., et al. Ectopic fat storage in the pancreas, liver, and abdominal fat depots: Impact on beta-cell function in individuals with impaired glucose metabolism. J Clin Endocrinol Metab 2011, 96:459-467.
17. Wittmeier K.D., Wicklow B.A., MacIntosh A.C., et al. Hepatic steatosis and low cardiorespiratory fitness in youth with type 2 diabetes. Obesity (Silver Spring, MD) 2012, 20:1034-1040.
18. Wicklow B.A., Wittmeier K.D., MacIntosh A.C., et al. Metabolic consequences of hepatic steatosis in overweight and obese adolescents. Diabetes Care 2012, 35:905-910.
19. Sellers E.A., Triggs-Raine B., Rockman-Greenberg C., Dean H.J. The prevalence of the HNF-1alpha G319S mutation in Canadian aboriginal youth with type 2 diabetes. Diabetes Care 2002, 25:2202-2206.
20. Triggs-Raine B.L., Kirkpatrick R.D., Kelly S.L., et al. HNF-1alpha G319S, a transactivation-deficient mutant, is associated with altered dynamics of diabetes onset in an Oji-Cree community. Proc Natl Acad Sci U S A 2002, 99:4614-4619.
21. Harries L.W., Sloman M.J., Sellers E.A., et al. Diabetes susceptibility in the Canadian Oji-Cree population is moderated by abnormal mRNA processing of HNF1A G319S transcripts. Diabetes 2008, 57:1978-1982.
22. Weedon M.N., Owen K.R., Shields B., et al. A large-scale association analysis of common variation of the HNF1alpha gene with type 2 diabetes in the U.K. Caucasian population. Diabetes 2005, 54:2487-2491.
23. American Diabetes Association Standards of Medical Care in Diabetes-2013. Diabetes Care 2013, 36(Suppl 1):S11-S66.
24. Committee of the Canadian Diabetes Association 2013 Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2013, 37(Suppl 1):S1-S212.
25. Cole T.J., Bellizzi M.C., Flegal K.M., Dietz W.H. Establishing a standard definition for child overweight and obesity worldwide: International survey. BMJ 2000, 320:1240-1243.
26. Lingvay I., Esser V., Legendre J.L., et al. Noninvasive quantification of pancreatic fat in humans. J Clin Endocrinol Metab 2009, 94:4070-4076.
27. Tran T.K., Vigneron D.B., Sailasuta N., et al. Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn Reson Med 2000, 43:23-33.
28. Sandrasegaran K., Lin C., Akisik F.M., Tann M. State-of-the-art pancreatic MRI. AJR 2010, 195:42-53.
29. Provencher S.W. Automatic quantitation of localized in vivo 1H spectra with LCModel. NIB 2001, 14:260-264.
30. Ball G.D., Shaibi G.Q., Cruz M.L., et al. Insulin sensitivity, cardiorespiratory fitness, and physical activity in overweight Hispanic youth. Obes Res 2004, 12:77-85.
31. 1H-magnetic resonance spectroscopy study. Circulation 2007, 116:1170-1175.
32. Zib I., Jacob A.N., Lingvay I., et al. Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes. J Invest Med 2007, 55:230-236.
33. Katzmarzyk P.T. Waist circumference percentiles for Canadian youth 11-18 y of age. Eur J Clin Nutr 2004, 58:1011-1015.
34. Hegele R.A., Cao H., Harris S.B., et al. Hepatocyte nuclear factor-1 alpha G319S: A private mutation in Oji-Cree associated with type 2 diabetes. Diabetes Care 1999, 22:524.
35. Unger R.H., Orci L. Diseases of liporegulation: New perspective on obesity and related disorders. FASEB 2001, 15:312-321.
36. Le K.A., Ventura E.E., Fisher J.Q., et al. Ethnic differences in pancreatic fat accumulation and its relationship with other fat depots and inflammatory markers. Diabetes Care 2011, 34:485-490.
37. Liu J., Young T.K., Zinman B., et al. Lifestyle variables, non-traditional cardiovascular risk factors, and the metabolic syndrome in an Aboriginal Canadian population. Obesity (Silver Spring, MD) 2006, 14:500-508.
38. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology (Baltimore, MD) 2004, 40:1387-1395.
39. Petersen K.F., Dufour S., Feng J., et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A 2006, 103:18273-18277.
40. Romeo S., Kozlitina J., Xing C., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature Genet 2008, 40:1461-1465.
41. Goran M.I., Walker R., Le K.A., et al. Effects of PNPLA3 on liver fat and metabolic profile in Hispanic children and adolescents. Diabetes 2010, 59:3127-3130.
42. Goran M.I., Walker R., Allayee H. Genetic-related and carbohydrate-related factors affecting liver fat accumulation. Curr Opin Clin Nutr Metab Care 2012, 15:392-396.
43. McCarthy E.M., Rinella M.E. The role of diet and nutrient composition in nonalcoholic Fatty liver disease. J Acad Nutr Dietet 2012, 112:401-409.
44. Keating S.E., Hackett D.A., George J., Johnson N.A. Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol 2012, 57:157-166.
45. Thanabalasingham G., Owen K.R. Diagnosis and management of maturity-onset diabetes of the young (MODY). BMJ 2011, 343:d6044.
46. Mendelson M., Cloutier J., Spence L., et al. Obesity and type 2 diabetes mellitus in a birth cohort of First Nation children born to mothers with pediatric-onset type 2 diabetes. Pediatr Diabetes 2011, 12:219-228.
47. Lim E.L., Hollingsworth K.G., Aribisala B.S., et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011, 54:2506-2514.
48. Mari A., Tura A., Pacini G., et al. Relationships between insulin secretion after intravenous and oral glucose administration in subjects with glucose tolerance ranging from normal to overt diabetes. Diabetic Med 2008, 25:671-677.